President

Shalini Singh, MD (Roche Diagnostics Solutions) Dr. Shalini Singh is a pathologist and is Head of Pathology at Roche Tissue Diagnostics in Tucson, AZ. She has been with Roche for 13 years. Her primary interests include Digital pathology, personalized healthcare, molecular pathology, translational oncology, and immunotherapy. She is licensed physician with expertise in molecular and genetic pathology and companion diagnostics. She is a Fellow of the College of American Pathologists and collaborates with CAP foundation Educational Grant for residents’ rotation at Roche Tissue Diagnostics. She is an expert in strategic partnerships between Pharma and Diagnostics collaboration.

President-Elect

David Ferber, MD (Leica Biosystems) Dr. David Ferber is a pathologist and Senior Medical and Scientific Affairs liaison at Leica Biosystems. He has greater than 20 years of experience in anatomic and clinical practice with special interest/expertise in genitourinary pathology. He has held many roles during his clinical career including director of the autopsy service, supervisor of pathology assistants, transitional resident faculty, pathology representative on Cancer Committee, and member of virtual tumor board project. He is a graduate of University of Wisconsin School of Medicine and Public Health and completed residency at Medical College of Wisconsin. He is a fellow of the College of American Pathologists and member of the Digital Pathology Society. He is a licensed physician particularly interested in digital pathology and innovation eager to take on the challenges of his role as medical science liaison.

Immediate Past President

Erico von Bueren, MD, PhD, MOR (Sakura Finetek USA, Inc.) Dr. Erico von Bueren is the Senior Director of Marketing and Strategy for Sakura Finetek USA, Inc. After his study and Doctorate in Medicine (Milano, Essen, Bochum, Frankfurt, Universities in Italy and Germany) and Masters in Operations Research (Aachen, Germany), Mr. von Bueren started his career in the pharmaceutical industry in medical, product and marketing management in several therapeutic areas (Ferring Pharmaceuticals and Schwarz Pharma/UCB). After 10 years, he switched to the in-vitro diagnostic industry concentrating on the fields of flow cytometry and anatomic pathology (Dako/Agilent, Denmark and U.S.A., and Thermo Fisher Scientific, U.S.A.). Now at Sakura Finetek USA, his focus in commercial and global product and market development resides in automating and standardizing anatomic pathology through continuous innovation.

Treasurer

Ghislain Noumsi, MD, MBA, SBB (Agilent Technologies Inc.) Dr. Ghislain Noumsi is Associate Vice-President, Global Head of Medical Affairs Pathology/CDx at Agilent Technologies Inc. Ghislain holds a Doctorate in Medicine (University of Bamako, Bamako, Mali), Specialist in Blood Bank Certificate (University of Texas Medical Branch, Galveston, TX) and a Master of Business Administration (Texas State University, San Marcos, TX). Dr. Noumsi started his professional career in hematopathology and transfusion medicine in Africa, studying red blood cells antigenic expression, alloimmunization and immune complexes formation during malaria and tuberculosis, resulting in multiple publications. He joined the pharmaceutical industry in medical affairs over 10 years ago and has held senior level positions in the U.S.A. and Asia-Pacific. Dr. Noumsi’s expertise includes strategy development centered around patient unmet needs, support to global commercial execution, key opinion leaders management and establishing research collaboration with leading academic institutions. His work spans across multiple laboratory medicine specialties including in vitro diagnostics, molecular diagnostics, hematopathology, pathology, and companion diagnostics.

Benefactor Director

Joshua Greenlee, MBA, IASSC CBB™, HT/HTL(ASCP)^cm (Sakura Finetek USA, Inc.) Joshua Greenlee is a Senior Product Manager & Laboratory Workflow/Productivity Strategist for Sakura Finetek USA, Inc. He has greater than 20 years of laboratory experience, primarily in anatomic pathology. He holds a Bachelor of Science in Biology, Master of Business Administration specializing in Project Management, and is dual ASCP certified as an HT/HTL(ASCP)cm. In addition to laboratory work, he spent 4 years working in the NAACLS accredited histology program at Phoenix College. He joined Sakura Finetek USA, Inc., in 2015. With his current position, as an IASSC Certified Black Belt in Lean Six Sigma, Joshua focuses on workflow and implementation of innovative automation solutions in anatomic pathology.

Benefactor Director

Robert Lott, HTL(ASCP) (Roche Diagnostic Solutions) Robert Lott is an Access Engagement Leader within the Global Access and Policy (GA&P) team at Roche Diagnostic Solutions/Ventana Medical Systems, Inc. in Tucson, AZ. Mr. Lott has been involved in anatomic pathology at various levels for more than 35 years. He has served as the National Society for Histotechnology (NSH) appointee to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS) Board of Directors. In addition, he served on the Histotechnology Examination Committee of the American Society of Clinical Pathologists (ASCP). Mr. Lott has a special interest in histology education and certification. He is a current adjunct faculty member for the Histotechnology Training Program at Harford Community College, Bel Air, MD. Mr. Lott also served as a NSH appointee to the CAP/NSH Histotechnology Committee at the College of American Pathologists from 2005 thru 2011and was reappointed to that committee in 2013. Mr. Lott was named the 2010 NSH Histotechnologist of the Year.